ArticlePhilosophical transactions. Series A, Mathematical, physical, and engineering sciences2011
Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy.
Article in Philosophical transactions. Series A, Mathematical, physical, and engineering sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 114 citations in OpenAlex.
- In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab.British journal of cancer · 2016Trial
- Advances in fully integrated wearable near-infrared spectroscopy: hardware innovations and biomedical applications.JPhys photonics · 2026Review
- Broad-Bandwidth Frequency-Domain Near-Infrared Spectroscopy System on a Chip.IEEE sensors journal · 2025Article
- Establishing the feasibility and reliability of broadband absorption spectroscopy for measuring cerebral water content in adults.Biomedical optics express · 2025Article
- Monte Carlo simulation of spatial frequency domain imaging for breast tumors during compression.Journal of biomedical optics · 2024Article
- Functional hemodynamic imaging markers for the prediction of pathological outcomes in breast cancer patients treated with neoadjuvant chemotherapy.Journal of biomedical optics · 2024Article
- Differentiating Primary and Recurrent Lesions in Patients with a History of Breast Cancer: A Comprehensive Review.Galen medical journal · 2024Article
- Water and lipid content of breast tissue measured by six-wavelength time-domain diffuse optical spectroscopy.Journal of biomedical optics · 2022Article
- Quantitative spatial mapping of tissue water and lipid content using spatial frequency domain imaging in the 900- to 1000-nm wavelength region.Journal of biomedical optics · 2022Article
- High optode-density wearable diffuse optical probe for monitoring paced breathing hemodynamics in breast tissue.Journal of biomedical optics · 2021Article
- Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography.Breast cancer research : BCR · 2021Article
- Direct measurement of the scattering coefficient.Biomedical optics express · 2021Article
- Shortwave-infrared meso-patterned imaging enables label-free mapping of tissue water and lipid content.Nature communications · 2020Article
- Characterization of bony anatomic regions in pediatric and adult healthy volunteers using diffuse optical spectroscopic imaging.Journal of biomedical optics · 2020Article
- Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens.Breast cancer research : BCR · 2020Article
- Strain wave elastography in response assessment to neo-adjuvant chemotherapy in patients with locally advanced breast cancer.The British journal of radiology · 2019Article
- Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment.Journal of biomedical optics · 2018Article
- Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer.Radiology · 2018Article
- Impact of errors in experimental parameters on reconstructed breast images using diffuse optical tomography.Biomedical optics express · 2018Article
- Emerging Breast Imaging Technologies on the Horizon.Seminars in ultrasound, CT, and MR · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Diffuse optical spectroscopic imaging (DOSI) non-invasively and quantitatively measures tissue haemoglobin, water and lipid. Pilot studies in small groups of patients demonstrate that DOSI may be useful for longitudinal monitoring and predicting breast cancer neoadjuvant chemotherapy pathological response. This study evaluates the performance of a bedside DOSI platform in 34 breast cancer patients followed for several months. DOSI optical endpoints obtained at multiple timepoints are compared with final pathological response. Thirty-six stage II/III breast cancers (34 patients) were measured in vivo with DOSI prior to, in the middle of and after the completion of pre-surgical neoadjuvant chemotherapy. Cancer therapies ranged from standard anthracyclines to targeted therapies. Changes in DOSI-measured parameters at each timepoint were compared against final surgical pathology. Absolute changes in the tumour-to-normal (T/N) ratio of tissue deoxyhaemoglobin concentration (ctHHb) and relative changes in the T/N ratio of a tissue optical index (TOI) were most sensitive and correlate to pathological response. Changes in ctHHb and TOI were significantly different between tumours that achieved pathological complete response (pCR) versus non-pCR. By therapy midpoint, mean TOI-T/N changes were 47±8 versus 20±5 per cent for pCR versus non-pCR subjects, respectively (Z=0.011). Changes in ctHHb and TOI scaled significantly with the degree of pathological response (non-, partial and complete). DOSI measurements of TOI separated pCR from non-pCR by therapy midpoint regardless of drug or dosing strategy. This approach is well suited to monitoring breast tumour response and may provide feedback for optimizing therapeutic outcomes and minimizing side-effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.